Deucravacitinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Deucravacitinib comprises 11 peer-reviewed publications across 10 journals, 2 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Psoriasis, Myositis, Autoimmune Diseases, and Recurrence. Most recent publication: Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials., Lancet, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
    Gold LS, Armstrong AW, Bissonnette R, et al. · Lancet · 2025
    PubMed: PMID 40976249 · NCT06220604
  2. Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
    Arriens C, Morand EF, Askanase AD, et al. · Adv Ther · 2025
    PubMed: PMID 40920289 · NCT05617677 (POETYK SLE-1) · Autoimmune Diseases
  3. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023
    PubMed: PMID 35129472 · NCT07352566 · Psoriasis
  4. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022
    PubMed: PMID 35788566 · NCT07352566 · Psoriasis
  5. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023
    PubMed: PMID 37672566 · NCT07352566 · Psoriasis
  6. TYK2: an emerging therapeutic target in rheumatic disease.
    Morand E, Merola JF, Tanaka Y, et al. · Nat Rev Rheumatol · 2024
    PubMed: PMID 38467779 · NCT07564271 · Myositis
  7. Successful treatment of recalcitrant amyopathic dermatomyositis with deucravacitinib in addition to intravenous immunoglobulin.
    McNamara ME, Tjahjono L · JAAD Case Rep · 2025
    PubMed: PMID 40642501 · NCT07564271 · Myositis
  8. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
    Aggarwal R, Rider LG, Ruperto N, et al. · Ann Rheum Dis · 2017
    PubMed: PMID 28385805 · NCT07564271 · Myositis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT04908189Arthritis, PsoriaticNumber of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16
Week 16
Deucravacitinib169 Participants
Placebo123 Participants
NCT04908202Arthritis, PsoriaticPercentage of Participants With ACR 20 Response at Week 16
Week 16
Placebo-Controlled Period - Deucravacitinib 6 mg QD54.2 percentage of participants
Placebo-Controlled Period - Placebo34.1 percentage of participants

Publications by year

2013–2025: 11 publications.

2013
1
2016
1
2017
1
2022
2
2023
2
2024
1
2025
3

Publications by indication

Psoriasis (4)

  • First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Ann Surg · 2023 · PMID 35129472 · NCT07352566
  • Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Sci Transl Med · 2023 · PMID 37672566 · NCT07352566
  • A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Nat Biotechnol · 2022 · PMID 35788566 · NCT07352566
  • An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Sci Transl Med · 2016 · PMID 25904741 · NCT07352566

Myositis (4)

  • Successful treatment of recalcitrant amyopathic dermatomyositis with deucravacitinib in addition to intravenous immunoglobulin.
    JAAD Case Rep · 2025 · PMID 40642501 · NCT07564271
  • TYK2: an emerging therapeutic target in rheumatic disease.
    Nat Rev Rheumatol · 2024 · PMID 38467779 · NCT07564271
  • 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
    Ann Rheum Dis · 2017 · PMID 28385805 · NCT07564271
  • Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness.
    Skelet Muscle · 2013 · PMID 23758833 · NCT07564271

Autoimmune Diseases (1)

  • Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
    Adv Ther · 2025 · PMID 40920289 · NCT05617677

Recurrence (1)

Publications by journal

Trial-results highlights

The clinical evidence base for deucravacitinib in the treatment of Psoriatic Arthritis includes findings from pivotal studies. One such investigation, NCT04908189, reported on a primary outcome measuring the number of participants who achieved an American College of Rheumatology (ACR) 20 response at Week 16. In NCT04908189, the arm receiving deucravacitinib included 169 Participants who met the ACR 20 criteria. For comparison, the placebo arm in the same trial reported that 123 Participants achieved an ACR 20 response at Week 16.

Further data for Psoriatic Arthritis comes from another pivotal trial, NCT04908202. This study specifically evaluated the percentage of participants achieving an ACR 20 response at Week 16 as its primary endpoint. During the placebo-controlled period of NCT04908202, the arm treated with deucravacitinib 6 mg QD demonstrated an ACR 20 response in 54.2 percentage of participants. In the same trial and during the placebo-controlled period, the placebo arm reported that 34.1 percentage of participants achieved an ACR 20 response.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Deucravacitinib publications (11)

2025 (3 papers)

  1. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
    Gold LS, Armstrong AW, Bissonnette R, et al. · Lancet · 2025 · Derived
    PubMed: PMID 40976249 · NCT06220604
  2. Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
    Arriens C, Morand EF, Askanase AD, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 40920289 · NCT05617677 (POETYK SLE-1) · Autoimmune Diseases
  3. Successful treatment of recalcitrant amyopathic dermatomyositis with deucravacitinib in addition to intravenous immunoglobulin.
    McNamara ME, Tjahjono L · JAAD Case Rep · 2025 · Background
    PubMed: PMID 40642501 · NCT07564271 · Myositis

2024 (1 paper)

  1. TYK2: an emerging therapeutic target in rheumatic disease.
    Morand E, Merola JF, Tanaka Y, et al. · Nat Rev Rheumatol · 2024 · Background
    PubMed: PMID 38467779 · NCT07564271 · Myositis

2023 (2 papers)

  1. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
    PubMed: PMID 35129472 · NCT07352566 · Psoriasis
  2. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
    PubMed: PMID 37672566 · NCT07352566 · Psoriasis

2022 (2 papers)

  1. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
    PubMed: PMID 35788566 · NCT07352566 · Psoriasis
  2. Deucravacitinib for the Treatment of Psoriatic Disease.
    Lé AM, Puig L, Torres T, et al. · Am J Clin Dermatol · 2022 · Background
    PubMed: PMID 35960487 · NCT07013838 · Recurrence

2017 (1 paper)

  1. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
    Aggarwal R, Rider LG, Ruperto N, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 28385805 · NCT07564271 · Myositis

2016 (1 paper)

  1. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25904741 · NCT07352566 · Psoriasis

2013 (1 paper)

  1. Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness.
    Rayavarapu S, Coley W, Kinder TB, et al. · Skelet Muscle · 2013 · Background
    PubMed: PMID 23758833 · NCT07564271 · Myositis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).